Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 5/20 | 0.49 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.33 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.33 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10281116 | 0.91 | PDE4D (0.54) | PDE4DPDE3AAPPCISD1POLB | |
| Azosemide SCHEMBL30754398 | 0.89 | PDE4D (0.70) | PDE4DPDE3AAPPCISD1POLB | |
| Azosemide SCHEMBL4421865 | 0.89 | PDE4D (0.70) | PDE4DPDE3AAPPCISD1POLB | |
| Azosemide SCHEMBL48976 | 0.89 | PDE4D (0.70) | PDE4DPDE3AAPPCISD1POLB | |
| Azosemide SCHEMBL8988688 | 0.88 | PDE4D (0.69) | PDE4DPDE3AAPPCISD1POLB | |
| Azosemide SCHEMBL231405 | 0.83 | PDE4D (0.58) | PDE4DPDE3AAPPCISD1POLB | |
| SCHEMBL22852404 | 0.83 | APP (0.71) | PDE4DPDE3AAPPCISD1POLB | |
| Azosemide SCHEMBL230626 | 0.82 | PDE4D (0.62) | PDE4DPDE3AAPPCISD1POLB | |
| SCHEMBL10169463 | 0.81 | PDE4D (0.47) | PDE4DPDE3ACISD1POLBTSHR | |
| SCHEMBL12522802 | 0.81 | PDE4D (0.55) | PDE4DPDE3ACISD1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194732-A1 | MULTI-API LOADING PRODRUGS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
| US-20160024011-A1 | Multi-API Loading Prodrugs | ALKERMES PHARMA IRELAND LTD (IE) | 2016-01-28 | — | — | US | disclosed |
| US-20120202823-A1 | Multi-API Loading Prodrugs | ALKERMES, INC. | 2012-08-09 | — | — | US | disclosed |
| US-7544711-B2 | Use of nitroderivatives in urinary incontinence | NICOX S.A. (FR) | 2009-06-09 | — | — | US | disclosed |
| US-7282519-B2 | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024011-A1 | Multi-API Loading Prodrugs | AADAC, PAICS, ABCG2 | PDE4D 729/4885PDE3A 341/4885APP 2849/4885 |
| US-20120202823-A1 | Multi-API Loading Prodrugs | AADAC, PAICS, ABCG2 | PDE4D 729/4885PDE3A 341/4885APP 2849/4885 |
| US-20180194732-A1 | MULTI-API LOADING PRODRUGS | AADAC, PAICS, ABCG2 | PDE4D 729/4885PDE3A 341/4885APP 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.